Friday, July 10, 2026
🇺🇸 FDA

Drug profile · INN

cisplatinum

cisplatinum is a dna inhibitor.

NMPA: clinical trials
Patents linked 0
Pipeline programs 6
News articles 0
Drug details — cisplatinum
Class
—
Route
—
Patents
0
Programs
6
Data quality
0.70
← All drugs Search patents Pipeline programs Drug news hub Event calendar

Quick answer

cisplatinum is a dna inhibitor.

Key facts

INN cisplatinum
Mechanism DNA inhibitor
Target DNA

Mechanism of action

DNA inhibitor

Primary target: DNA

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Search pipeline
  1. 17000139BLC3001 Phase 3 · Janssen-Cilag International N.V · Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder
  2. INCMGA 0012-304 Phase 3 · Incyte · Metastatic nonsquamous or squamous non-small cell lung cance
  3. JZP598-302 Phase 3 · Jazz Pharmaceuticals Ireland · BTC - Biliary Tract Cancer
  4. R2810-ONC-2268 Phase 2 · Anaxis Pharma · Non-Small Cell Lung Cancer
  5. RMC-LUNG-101A Phase 1 · Revolution Medicines · Lung Cancer
  6. RMC-LUNG-101B Phase 1 · Revolution Medicines · Lung Cancer

Related & competitor drugs

Browse all drugs
  1. acyclovir Human herpesvirus 1 DNA polymerase inhibitor
  2. acyclovir sodium Human herpesvirus 1 DNA polymerase inhibitor
  3. azacitidine Antineoplastic and immunomodulating agents (L01)
  4. bleomycin sulfate DNA inhibitor
  5. busulfan Antineoplastic and immunomodulating agents (L01)
  6. capecitabine Antineoplastic and immunomodulating agents (L01)

Frequently asked questions

What is cisplatinum?

cisplatinum is a dna inhibitor.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.